What is MacroGenics?
MacroGenics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative monoclonal antibody-based therapeutics, primarily targeting cancer. Leveraging its proprietary technology platforms and expertise in protein engineering, MacroGenics has successfully generated a portfolio of product candidates. The company has also established strategic collaborations with prominent global pharmaceutical and biotechnology firms, amplifying its research and development capabilities and market reach. Its focus on novel antibody therapeutics positions it at the forefront of oncology treatment innovation.
How much funding has MacroGenics raised?
MacroGenics has raised a total of $559M across 10 funding rounds:
Series D
$25M
Grant
$9.8M
Stock Offering
$83.8M
Stock Offering
$76.7M
Stock Offering
$141M
Stock Offering
$23.6M
Stock Offering
$110M
Series D (2008): $25M featuring Nextech Venture, Eli Lilly and Company, RiverVest, Arcus Ventures, TPG Ventures, Alta Partners, Mitsubishi UFJ, Ventures West, Innovis Investments, InterWest Partners, OrbiMed, CIDC, Red Abbey Venture Partners, and Alexandria
Grant (2010): $9.8M backed by National Institutes of Health
Stock Issuance/Offering (2013): $83.8M with participation from Undisclosed
Stock Issuance/Offering (2014): $76.7M led by Undisclosed
Stock Issuance/Offering (2015): $141M supported by Undisclosed
Stock Issuance/Offering (2017): $23.7M featuring Undisclosed
Stock Issuance/Offering (2018): $110M backed by Undisclosed
Key Investors in MacroGenics
MPM Capital
MPM Capital is a venture capital firm specializing in early-stage investments within the life sciences sector, focusing on converting scientific breakthroughs into therapeutic solutions.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms.
TPG Ventures
TPG Ventures is a global investment firm that supports business growth across diverse industries, providing investment management and capital solutions with a focus on identifying opportunities and building long-term value.
What's next for MacroGenics?
With substantial capital raised, MacroGenics is poised for accelerated development and potential commercialization of its lead product candidates. The recent major strategic investment suggests a focus on scaling operations, advancing clinical trials, and potentially expanding its therapeutic pipeline into new indications or modalities. Future strategic moves may involve further collaborations, licensing agreements, or preparations for market entry, contingent on clinical trial outcomes and regulatory approvals. The company's sustained access to significant investment capital highlights its potential to make a substantial impact on cancer treatment.
See full MacroGenics company page
